- Home
- DSP vs AVR Comparison
DSP vs AVR Comparison
Compare DSP & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- AVR
- Stock Information
- Founded
- DSP 1999
- AVR 1999
- Country
- DSP United States
- AVR Australia
- Employees
- DSP N/A
- AVR N/A
- Industry
- DSP EDP Services
- AVR
- Sector
- DSP Technology
- AVR
- Exchange
- DSP Nasdaq
- AVR NYSE
- Market Cap
- DSP 291.3M
- AVR 241.5M
- IPO Year
- DSP 2021
- AVR 2024
- Fundamental
- Price
- DSP $14.12
- AVR $4.21
- Analyst Decision
- DSP Strong Buy
- AVR Strong Buy
- Analyst Count
- DSP 8
- AVR 4
- Target Price
- DSP $21.75
- AVR $16.50
- AVG Volume (30 Days)
- DSP 263.8K
- AVR 254.6K
- Earning Date
- DSP 05-06-2025
- AVR 05-20-2025
- Dividend Yield
- DSP N/A
- AVR N/A
- EPS Growth
- DSP N/A
- AVR N/A
- EPS
- DSP 0.13
- AVR N/A
- Revenue
- DSP $306,484,000.00
- AVR $2,703,000.00
- Revenue This Year
- DSP $19.25
- AVR $29.52
- Revenue Next Year
- DSP $16.72
- AVR $204.83
- P/E Ratio
- DSP $109.37
- AVR N/A
- Revenue Growth
- DSP 30.64
- AVR N/A
- 52 Week Low
- DSP $8.62
- AVR $2.34
- 52 Week High
- DSP $26.33
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- DSP 55.48
- AVR N/A
- Support Level
- DSP $12.58
- AVR N/A
- Resistance Level
- DSP $15.31
- AVR N/A
- Average True Range (ATR)
- DSP 0.80
- AVR 0.00
- MACD
- DSP 0.15
- AVR 0.00
- Stochastic Oscillator
- DSP 81.76
- AVR 0.00
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.